



**EIP**★  
European Immunogenicity Platform

---

# 10th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals

Session 4: Biosimilars



1. EIP Biosimilars Working Group update
2. Immunogenicity assessment for an adalimumab biosimilar – Anita Rudy
3. Clinical and regulatory issues in immunogenicity testing for insulins – Sandeep Anthayle



# EIP Biosimilars Working Group update

Martin Ullmann

# Working Group Members

---

- Annick de Vries, Sanquin
- Arno Kromminga, ipm-biotech
- Dan Mytych, Amgen
- Gregor Schaffar, Sandoz
- James Munday, Covance
- Janka Ryding, Wieslab
- Jasja Wolthoorn, Sanquin
- Martin Ullmann (Lead), Fresenius-Kabi
- Sophie Tourdot, EIP & Pfizer

# Working Group Project Charter

---

## **Problem statement:**

How to evaluate IMG in the context of biosimilars?

- When ADAs show no clinical impact and ADA incidence are comparable, is it necessary to do a full evaluation (e.g. kinetics ....)?
- How to best validate an ADA/NAb assay for Biosimilars
- How to best measure ADA/NAb for Biosimilars
- How to extrapolate in the context of only one disease population, eventually even being immune suppressed and with limited immunogenicity data?
- Review 483's and come up with recommendations ..?
- How to generate data to support inter-changeability (e.g. number of times switching) in different regulatory context (EMA/FDA)
- Understand what the perspective on IMG is for a non-bioanalytical person? E.g. medical, commercial, .....? Once defined, (how) can we adapt to better meet such "expectations"?

# Working Group Project Charter

---

## **Key Deliverables**

- Publication
- Workshop
- Presentation at EIP etc.
- Questionnaire (pre-conference and within conference)
- Explore collaboration with academia to advance/understand IMG

## **Key stakeholders**

- Scientist working within biosimilars and on immunogenicity
- Biosimilar companies interested to advance their understanding of IMG
- Regulatory authorities

